A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer
Phase of Trial: Phase III
Latest Information Update: 13 Jul 2017
At a glance
- Drugs Napabucasin (Primary) ; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Boston Biomedical
- 07 Jul 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 19 Dec 2016 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.